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RNA polymerase (RNAP) binding protein A (RbpA) is
essential for mycobacterial viability and regulates transcription
initiation by increasing the stability of the RNAP-promoter
open complex (RPo). RbpA consists of four domains: an
N-terminal tail (NTT), a core domain (CD), a basic linker, and a
sigma interaction domain. We have previously shown that
truncation of the RbpA NTT and CD increases RPo stabilization by RbpA, implying that these domains inhibit this activity
of RbpA. Previously published structural studies showed that
the NTT and CD are positioned near multiple RNAP-σA holoenzyme functional domains and predict that the RbpA NTT
contributes speciﬁc amino acids to the binding site of the
antibiotic ﬁdaxomicin (Fdx), which inhibits the formation of
the RPo complex. Furthermore, deletion of the NTT results in
decreased Mycobacterium smegmatis sensitivity to Fdx, but
whether this is caused by a loss in Fdx binding is unknown. We
generated a panel of rbpA mutants and found that the RbpA
NTT residues predicted to directly interact with Fdx are
partially responsible for RbpA-dependent Fdx activity in vitro,
while multiple additional RbpA domains contribute to Fdx
activity in vivo. Speciﬁcally, our results suggest that the RPostabilizing activity of RbpA decreases Fdx activity in vivo. In
support of the association between RPo stability and Fdx activity, we ﬁnd that another factor that promotes RPo stability in
bacteria, CarD, also impacts to Fdx sensitivity. Our ﬁndings
highlight how RbpA and other factors may inﬂuence RNAP
dynamics to affect Fdx sensitivity.

Mycobacterium tuberculosis is the causative agent of the
disease tuberculosis, which resulted in an estimated 1.5 million
deaths worldwide in 2019 (https://www.who.int/publications/
i/item/9789240013131). New strategies are necessary to ﬁght
this global health crisis, including the development of novel
therapies. Bacterial transcription is a druggable essential process in M. tuberculosis, demonstrated by the transcription
inhibitor rifampicin’s continued status as a cornerstone of
tuberculosis treatment. Bacterial transcription is carried out by
an RNA polymerase (RNAP) comprised of ﬁve subunits
(α2ββ’ω), referred to as the core RNAP, and a sixth dissociable
‡
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subunit (σ) that when bound to core RNAP forms a complex
termed the RNAP holoenzyme. Mycobacterial transcription
initiation in vivo also requires two additional essential RNAPinteracting proteins, RbpA and CarD (1–6). RbpA and CarD
regulate transcription initiation by binding to the RNAP and
modulating the kinetics of RNAP-promoter open complex
(RPo) formation and RNAP promoter escape (2, 5–10).
RbpA is comprised of four structural domains, including the
N-terminal tail (NTT), core domain (CD), basic linker (BL),
and sigma interaction domain (SID) (4, 10, 11). Most of the
characterization of RbpA has focused on the BL and SID. The
RbpA SID domain directly interacts with σ region 1.2, σ nonconserved region, and σ region 2.3 in group I (M. tuberculosis
σA) and group II (M. tuberculosis σB) σ factors (4, 5, 10, 12–14).
The SID domain is both necessary and sufﬁcient for RbpA to
associate with the RNAP holoenzyme (5). An arginine at position 88 in the M. tuberculosis RbpA SID is critical for the
interaction with σA and σB (5, 15). The M. tuberculosis RbpA
BL contains several positively charged residues, including K73,
K74, K76, and R79, that are positioned to interact with the
negatively charged DNA phosphate backbone near the upstream edge of RPo (4, 10). Alanine substitution at either R79 in
the BL or R88 in the SID has demonstrated that the interactions between RbpA and the RNAP and DNA are necessary for RbpA to increase RPo stability during transcription
initiation (5, 10, 14). In vivo, R79A or R88A substitutions in
RbpA result in upregulation of some genes and downregulation
of other genes, suggesting that the outcome of RbpA activity
may be promoter dependent, possibly due to differences in the
kinetics of transcription initiation at each promoter (5, 16, 17).
Much less is known about the functions performed by the
RbpA NTT and CD. Deletion of the RbpA NTT increases the
ability of RbpA to stabilize RPo, and deletion of both the RbpA
NTT and CD further increases RPo stability, indicating that
both domains antagonize RbpA-mediated stabilization of RPo
(5, 10). Structural analysis of RbpA bound to the
M. tuberculosis RNAP-σA RPo shows that the RbpA NTT is
positioned near the RNA exit channel, possibly contacting the
RNAP β switch 3 region (Sw3), β ﬂap, β0 lid, σA region 3.2
(σA3.2, also referred to as the σ “ﬁnger” domain), and the β0 zinc
binding domain (ZBD), while the RbpA CD is positioned near
the RNAP β0 zipper and RNAP β0 ZBD (10, 11). These RNAP
J. Biol. Chem. (2022) 298(4) 101752
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RbpA effects on RNAP and ﬁdaxomicin activity
structural domains have been characterized to varying levels in
Escherichia coli, which lacks RbpA. The RNAP β Sw3 is one of
ﬁve switch regions that are thought to undergo conformational
changes during transcription initiation (18). RNAP β Sw3 is
positioned near the template DNA −3 and −4 nucleotides,
raising the possibility that RNAP β Sw3 could play a role in
DNA template strand positioning (19). The RNAP β ﬂap,
which includes the ﬂap tip helix that interacts with σ region 4,
is important for positioning σ region 4 for interaction with
the −35 element of the promoter (20) and represents a common binding interface for transcription factors that directly
interact with σ (21, 22). The RNAP β0 lid separates the RNA/
DNA hybrid as part of the RNA exit channel and is required
for RPo stability and transcription in E. coli and Thermus
aquaticus (23, 24). RNAP σ703.2 plays a role in initiating
nucleotide triphosphate binding by positioning the DNA
template strand for interaction with −4 and −5 nucleotides of
the DNA template strand, which affects abortive transcription
and promoter escape (25–28). Both the RNAP β0 ZBD and β0
zipper facilitate RPo formation on promoters with −35 elements that form weak interactions with σ by making promoter
contacts within the spacer region between the −10 and −35
motifs (29, 30).
The positioning of the RbpA NTT and CD near multiple
different structural and functional domains of the RNAP-σA
holoenzyme implies that the RbpA NTT and CD could impact
RNAP activity through a number of mechanisms. However, it
is unclear what contacts between the RbpA NTT/CD and the
RNAP mediate the antagonism of RPo stability. In addition,
structural studies indicate that the RbpA NTT is positioned in
the RNAP-σA holoenzyme complex in such a way that it
contributes to the binding site for the antibiotic ﬁdaxomicin
(Fdx) (11), which is used to treat Clostridium difﬁcile infections. Fdx inhibits transcription initiation by binding the
RNAP and blocking the closing of the RNAP clamp that occurs during RPo formation (11, 31). Deletion of the RbpA NTT
decreases sensitivity of M. tuberculosis RNAP to Fdx in vitro
and in vivo (11), which is proposed to be due to the loss of
RbpA’s contribution to the RNAP-Fdx binding interface.
However, given that RbpA NTT also decreases RPo stability (5)
and is predicted to interact with σA3.2, which is known to affect
Fdx activity (11, 32), it is possible that RbpA may impact Fdx
activity by additional mechanisms. In this study, we interrogate
the roles played by residues within the NTT in RbpAdependent Fdx sensitivity and ﬁnd that the amino acids predicted by the structural studies to interact with Fdx do partially
contribute to Fdx activity in vitro. However, we also ﬁnd that
RbpA’s impact on Fdx activity in vivo extends beyond the role
of the NTT in binding the antibiotic, revealing a dominant
contribution for RNAP conformation in Fdx sensitivity.

Results
RbpA E17 and R10 synergize to promote Fdx activity against
M. tuberculosis RNAP-σA in vitro
In vitro assays that monitor the production of a 3-nucleotide
product as a proxy of RPo stability have shown that addition of
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Fdx to M. tuberculosis RNAP-σA holoenzymes reduces the
amount of RPo formed following the subsequent addition of
NTPs and a DNA template harboring the M. tuberculosis
rrnAP3 promoter (11). We used this assay with a range of Fdx
concentrations to calculate the concentration of Fdx that inhibits 50% of RPo (IC50) formed by RNAP-σA on the rrnAP3
promoter in the presence or absence of different RbpA variants. Addition of WT RbpAMtb (RbpAMtbWT) to the RNAP-σA
holoenzyme increases the sensitivity of the RNAP-σA holoenzyme to Fdx in this assay, and this is dependent on the
presence of the NTT (deleted in the RbpAMtb26–111 and
RbpAMtb72–111 mutants) (11) (Fig. 1, A–C). Deletion of both
the RbpA NTT and CD resulted in an IC50 within the conﬁdence interval of the IC50 when the NTT alone was deleted
(Fig. 1, B and C), indicating that the presence of the RbpA CD
does not affect Fdx activity against M. tuberculosis RNAP-σA
in vitro. In contrast, an R88A substitution in the RbpA SID
that weakens the interaction between RbpA and the RNAP
resulted in an IC50 that was lower and outside the conﬁdence
interval, compared to RbpAMtbWT, suggesting that domains
outside of the NTT could increase Fdx sensitivity (Fig. 1C).
Importantly, a saturating concentration of RbpA protein was
used in these assays, and therefore, the different effects of
RbpA variants on Fdx sensitivity in this assay should not be a
result of altered proportions of RbpA-bound RNAP-σA
complexes.
Structural studies predicted that the NTT contributes
contacts with Fdx when the antibiotic is bound to the
M. tuberculosis RNAP-σA holoenzyme (PDB: 6BZO), specifically through a water-mediated interaction between RbpA
E17 and Fdx (Fig. 1D) (11). To determine whether the predicted interaction between Fdx and RbpA E17 underpins
NTT-dependent Fdx activity, we calculated the IC50 of Fdx in
the presence of RbpAMtbWT versus an RbpAMtbE17A mutant
protein. The activity of Fdx against the M. tuberculosis RNAPσA in the presence of RbpAMtbE17A was nearly equal to Fdx
activity against the M. tuberculosis RNAP-σA in the presence
of RbpAMtbWT, indicating that alterations in the size and
charge of the amino acid side chain at RbpA NTT position 17
do not impact Fdx activity against the M. tuberculosis RNAPσA (Fig. 1, B and C).
The structure in Boyaci et al. (11) also highlights potential
van der Waals interactions between RbpA R10 and Fdx in the
RNAP-σA holoenzyme bound to double stranded forked DNA
(PDB: 6BZO) (Fig. 1D); however, given the distance between
RbpA R10 and Fdx, one would predict this to be a weak
interaction. In a separate structure of RbpA bound to
M. tuberculosis RNAP-σA in complex with two doublestranded forked DNA molecules that mimics the RPo (PDB:
6C04), the RbpA R10 positively charged side chain is positioned within 2.4 Å of the negatively charged side chain of
σA3.2 D441, forming a polar interaction (11) (Fig. 1E). Fdx
activity against E. coli RNAP-σ70 holoenzyme lacking σ703.2 is
attenuated approximately 20-fold (32), indicating that σ703.2
contributes to Fdx inhibition of the E. coli RNAP. Therefore, if
RbpA R10 interacts with σA3.2, this may also affect Fdx activity.
To examine whether RbpA R10 contributes to M. tuberculosis
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Figure 1. RbpA E17 and R10 synergize to promote Fdx activity against M. tuberculosis RNAP-σA in vitro. A, schematic of RbpA’s four domain structure
including the location of the substituted residues, R10, E17, R79, R88, and the two M. tuberculosis truncation mutants, RbpA 26–111 lacking the NTT, and
RbpA 72–111 lacking the NTT and CD. B, representative gels showing Fdx (0 μM, 0.01 μM, 0.1 μM, 1.0 μM, 10 μM, and 100 μM) inhibition of M. tuberculosis
RNAP-σA production of three nucleotide transcripts alone or in complex with RbpAMtbWT, RbpAMtbR10A, RbpAMtbE17A, RbpAMtbR10A/E17A, RbpAMtbR79A,
RbpAMtbR88A, RbpAMtb26–111, or RbpAMtb72–111 from a linear dsDNA template containing positions −80 to +70 of M. tuberculosis rrnAP3 (relative to the +1
transcription start site). C, dose–response curves of the experiments shown in (A). The curves are generated from at least four replicates from at least two
different experiments. Percent inhibition at each Fdx concentration included in the plots compared to no drug is depicted as the mean ± SD. The IC50 for
each replicate was calculated by nonlinear regression analysis with four-parameter (EC50, Hill Slope, top and bottom curve plateaus) ﬁtting of log
transformed Fdx concentration versus normalized response, with the mean IC50 and 95% conﬁdence interval listed in the table. D, structural modeling of
Fdx binding pocket on the RbpA-bound M. tuberculosis RNAP-σA from PDB structure 6BZO. Fdx and RNAP residues involved in the RNAP-Fdx binding
interface are shown with PyMol stick representation while the rest of the structure is shown with PyMol cartoon representation. Polar interactions are
indicated by red dashed lines, and potential van der Waals interactions are shown as gray lines. E, structural modeling of RbpA-bound M. tuberculosis RNAPσA from PDB structure 6C04. RbpA R10 and RNAP σA D441 are shown with PyMol stick representation while the rest of the structure is shown with PyMol
cartoon representation. The polar interaction between RbpA R10 and RNAP σA D441 is indicated by the red dashed line. CD, core domain; Fdx, ﬁdaxomicin;
NTT, N-terminal tail; RbpA, RNA polymerase binding protein A; RNAP, RNA polymerase.

RNAP-σA Fdx sensitivity, we measured Fdx IC50 against the
M. tuberculosis RNAP-σA in the presence of RbpAMtbR10A.
Similar to the RbpAMtbE17A mutant, we observed no change in
Fdx IC50s against the M. tuberculosis RNAP-σA in the

presence of RbpAMtbR10A compared to RbpAMtbWT (Fig. 1, B
and C), indicating that the R10 residue is not required for
RbpA NTT-dependent Fdx activity. To determine the effect of
disrupting the contacts made by the both RbpA E17 and R10,
J. Biol. Chem. (2022) 298(4) 101752
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we measured the Fdx IC50 against M. tuberculosis RNAP-σA
in the presence of RbpAMtbR10A/E17A. Mutating both the R10
and E17 residues resulted in an approximately 3-fold increase
in the Fdx IC50 compared to RbpAMtbWT, although this was
still at least 5-fold lower than RbpA mutants lacking the entire
NTT (RbpAMtb26–111 and RbpAMtb72–111) (Fig. 1, B and C).
These data indicate that loss of one of these residues increases
the importance of the other for Fdx activity, but additional
mechanisms also contribute to NTT-dependent Fdx activity
in vitro.
Multiple RbpA domains impact Fdx activity in vivo
Previous work showed that truncation of the RbpA NTT
decreases the sensitivity of Mycobacterium smegmatis to Fdx
(11). To investigate the effect of mutations in RbpA on Fdx
sensitivity in vivo, we used a strain we previously engineered
that expresses rbpAMtbWT at the attB site of M. smegmatis and

A

has the endogenous rbpA gene deleted (5). We then attempted
to replace the rbpAMtbWT gene at the attB site in M. smegmatis
with alleles encoding each of the RbpA mutants studied in
Figure 1 using a gene swapping method (5, 33, 34). We have
previously used this approach to generate an M. smegmatis
strain expressing rbpAMtb72–111, which has a deletion of both
the NTT and CD (Fig. 1A), as its only rbpA allele (5). However,
we were unable to generate a viable strain expressing
rbpAMtb26–111, which deletes only the NTT (Fig. 1A), in place
of rbpAMtbWT. In contrast, we were able to replace the
rbpAMtbWT allele with the M. smegmatis allele rbpAMsm28–114,
which has previously been used to study the NTT in
M. smegmatis (10, 11). Similar to our previous report with the
M. smegmatis strain expressing RbpAMtb72–111 (5),
RbpAMsm28–114 and RbpAMsm72–114 strains also exhibited a
slow growth phenotype (Fig. 2A), conﬁrming that while the
NTT and CD are not required for viability in M. smegmatis,
they are important domains for RbpA activity. We have also

C

B

Figure 2. Multiple RbpA domains impact Fdx activity in vivo. A, ratio of the doubling times of M. smegmatis strains expressing RbpAMtbR10A, RbpAMtbE17A,
RbpAMtbR10A/E17A, RbpAMsm28–114, or RbpAMsm72–114 as compared to the average doubling time for the strain expressing RbpAMtbWT. The mean ± SD from at
least two independent experiments with three replicates per experiment. B, zones of inhibition (ZOI) by Fdx on bacterial lawns of M. smegmatis expressing
RbpAMtbWT, RbpAMtbR10A, RbpAMtbE17A, RbpAMtbR10A/E17A, RbpAMtbR79A, RbpAMtbR88A, RbpAMsm28–114, RbpAMsm72–114, or RbpAMtb72–111 as the only copy of rbpA.
C, mean radii of ZOI ± SD from at least two experiments with at least three replicates at 100 μM, 250 μM, and 500 μM Fdx is plotted. For A and C, statistical
signiﬁcance of differences was analyzed by ANOVA and Tukey’s multiple comparison test. **p < 0.01; ***p < 0.001; ****p < 0.0001. All comparisons to
RbpAMtbWT were included in the analysis, but only statistically signiﬁcant comparisons are indicated in the ﬁgure. Fdx, ﬁdaxomicin; RbpA, RNA polymerase
binding protein A; RNAP, RNA polymerase.
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previously shown that M. smegmatis expressing RbpAMtbR88A
or RbpAMtbR79A as its only rbpA allele also exhibits a slow
growth phenotype due to the importance of RbpA’s interaction
with the RNAP and DNA (5). Using the gene swapping
approach, we found that the RbpAMtbR10A, RbpAMtbE17A, and
RbpAMtbR10A/E17A point mutants could support viability in
M. smegmatis and had no effect on growth rate compared to
RbpAMtbWT in LB media (Fig. 2A), indicating that these mutations do not affect RbpA’s essential role in M. smegmatis.
To examine the Fdx sensitivity of each M. smegmatis strain,
we used a zone of inhibition assay, similar to previous studies
(2, 11). By spreading approximately 2.5 × 108 colony forming
units of bacteria on an agar plate and spotting 10 μl of 100,
250, or 500 μM Fdx dissolved in dimethyl sulfoxide (DMSO)
onto a disk placed onto the plate, the bacteria form a lawn after

incubation at 37 C for 2 days, and a zone absent of bacterial
growth indicates growth inhibition by Fdx. DMSO had no
effect on M. smegmatis growth in this assay and did not
generate a zone of clearing on its own, whereas incubation of
M. smegmatis with Fdx resulted in growth inhibition (Fig. 2B).
We compared the radii of the zones of inhibition formed on
each M. smegmatis mutant with Fdx and reproduced previous
ﬁndings that deletion of the RbpA NTT results in resistance to
Fdx in vivo (RbpAMtb72–111, RbpAMsm28–114, and
RbpAMsm72–114 mutants in Fig. 2, B and C) (11), which is
consistent with the in vitro ﬁndings (Fig. 1, B and C). In
contrast, the RbpAMtbR10A, RbpAMtbE17A, and RbpAMtbR10A/
E17A
mutants were not more resistant to Fdx in vivo, despite
the trend observed in vitro of RbpAMtbR10A/E17A displaying
decreased Fdx sensitivity compared to RbpAMtbWT (Figs. 1, B
and C and 2, B and C). Strikingly, the M. smegmatis
RbpAMtbR79A and RbpAMtbR88A mutants, which have decreased
afﬁnity for DNA and the σ factor, respectively, were signiﬁcantly more sensitive to Fdx treatment (Fig. 2, B and C). These
in vivo data highlight the existence of other contributors to
RbpA’s effect on Fdx activity that exist in the bacteria but are
not recapitulated in the in vitro assay.
Effects on RPo stability correlate to sensitivity to Fdx in M.
smegmatis in vivo
Although the RbpA SID and BL domains are not predicted
to contact Fdx in structural models, mutations of residues
within the SID (R88A) and BL (R79A) still affected Fdx
sensitivity in vivo (Fig. 2, B and C). This suggests that the
relationship between RbpA and Fdx sensitivity is not limited to
the contribution of speciﬁc amino acids within the NTT for
Fdx binding to RbpA-bound RNAP-σA. Therefore, we investigated whether RbpA’s functional role during transcription
initiation contributed to its effects on Fdx sensitivity. During
transcription initiation, RbpA stabilizes RNAP-σA (or σB) RPo
(5, 8–10, 13, 14), which requires binding of the SID to the σ
factor and binding of the BL to the DNA (5). In contrast, the
NTT and CD antagonize RbpA’s RPo stabilizing activity (5, 10).
Using the 3-nucleotide transcription assay to measure RPo
stability in the absence of Fdx, we found that addition of
RbpAMtbWT to M. tuberculosis RNAP-σA and the rrnAP3

promoter increased RPo stability compared to no factor, and
this effect was abolished with the RbpAMtbR88A mutant (Fig. 3,
A and B), consistent with previously published stopped ﬂow
ﬂuorescence data (5). Addition of RbpAMtb72–111 to
M. tuberculosis RNAP-σA and the rrnAP3 promoter increased
RPo stability compared to RbpAMtbWT, while addition of the
RbpAMtbR10A/E17A mutant showed similar activity as compared
to RbpAMtbWT (Fig. 3, A and B), demonstrating that R10 and
E17 are not involved in RbpA’s activity on RPo stability.
The effect of these RbpA alleles on RPo stability mirrors the
pattern of Fdx sensitivity in vivo, where M. smegmatis strains
expressing RbpA alleles conferring higher RPo stability
(RbpAMtb72–111) in vitro were less sensitive to killing by Fdx.
Conversely, M. smegmatis strains expressing RbpA alleles
conferring decreased RPo stability (RbpAMtbR88A) in vitro were
more sensitive to killing by Fdx. This correlation led us to
further investigate the relationship between RPo stability and
Fdx sensitivity. CarD is another essential transcription factor
in mycobacteria that functions to stabilize RPo (1, 7, 8, 10, 35,
36). We reasoned that if RPo stability was linked to Fdx activity
in vivo, then M. smegmatis strains expressing the CarDMtbR25E
mutant allele, which has a weaker afﬁnity for the RNAP and is
defective in stabilizing RPo (2, 7, 35) would be more sensitive
to Fdx than M. smegmatis expressing CarDMtbWT. Indeed,
when we performed the zone of inhibition assays on these
strains, we found that the R25E mutation in CarD also
increased the sensitivity of M. smegmatis to Fdx (Fig. 3, C and
D). In summary, our experiments uncover a relationship between RPo stability and Fdx sensitivity in M. smegmatis
(Table 1), suggesting that the role of RbpA for Fdx sensitivity
in mycobacteria may involve RbpA’s functional activity during
transcription initiation in addition to the role of the RbpA
NTT in Fdx binding. In addition, these studies highlight that
other factors that regulate RPo stability, such as CarD, could
also affect sensitivity to Fdx.

Discussion
Prior studies on RbpA have focused almost exclusively on
the SID interaction with σ factor and the BL interaction with
DNA, leaving the NTT and CD largely uncharacterized.
Structural studies have provided tremendous insight into the
potential interactions between the NTT and CD with multiple
RNAP-σA holoenzyme domains as well as the antibiotic Fdx
(10, 11, 37). Herein, we test the prediction that RbpA R10 and
E17 contribute contacts with the antibiotic Fdx that are
important for RbpA’s NTT-dependent activity against
M. tuberculosis RNAP-σA. We ﬁnd that in vitro, combined
mutation of both residues affects the IC50 of Fdx activity
against the M. tuberculosis RNAP-σA (Fig. 1, B and C); however, it is still not clear whether RbpA R10 and E17 promote
RbpA NTT-dependent Fdx activity through direct interaction
with Fdx or through an alternative mechanism. Maintenance
of partial Fdx activity against M. tuberculosis RNAP-σA bound
by RbpAMtbR10A/E17A in vitro indicates that additional RbpA
NTT residues, or perhaps the entire structural domain,
mediate RbpA NTT-dependent Fdx activity. In addition, the
J. Biol. Chem. (2022) 298(4) 101752
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Figure 3. RPo stability in associated with Fdx sensitivity in vivo. A, representative gels of three nucleotide transcripts produced by M. tuberculosis RNAPσA alone or in complex with RbpAMtbWT, RbpAMtb72–111, RbpAMtbR10/E17A, or RbpAMtbR88A from a plasmid DNA template containing positions −39 to +4 of
M. tuberculosis rrnAP3 relative to the +1 transcription start site. B, ratio of transcript produced as compared to the average of “No Factor” replicates included
on the same gel. Results are plotted as individual values with the mean ± SD shown. Statistical signiﬁcance of differences was determined by ANOVA and
Tukey’s multiple comparison test. ‘ns’, not signiﬁcant; **p < 0.01; ****p < 0.0001. C, zones of inhibition (ZOI) by Fdx on bacterial lawns of M. smegmatis
expressing CarDMtbWT or CarDMtbR25E as the only copy of carD. D, mean radii of ZOI ± SD from at least two experiments with at least three replicates at
100 μM, 250 μM, and 500 μM Fdx is plotted. Statistical signiﬁcance was analyzed by two-tailed Welch’s t test. *p < 0.05; **p < 0.01. Fdx, ﬁdaxomicin; RbpA,
RNA polymerase binding protein A; RPo, RNAP-promoter open complex.

RbpAMtbR10A/E17A mutant did not alter Fdx sensitivity in
M. smegmatis (Fig. 2), indicating that those residues play less
of a role in Fdx activity in vivo. The R88A substitution that
weakens RbpA’s interaction with the RNAP in vivo (5), and
thus would be expected to decrease M. smegmatis sensitivity to
Fdx since less RbpA would be associated with RNAP-σA, also
unexpectedly increased M. smegmatis sensitivity to Fdx. Taken
together, these observations reveal differences in the effects of
RbpA mutants on Fdx sensitivity in vitro compared to in vivo
and support a model where RbpA can impact Fdx activity
independent of its direct contacts with the antibiotic.
These discrepancies between the measured sensitivities
in vitro versus in vivo may be due in part to the limited scope of
the in vitro assay used here and in previous studies to probe
Fdx activity (11), where Fdx is added to RbpA and RNAP-σA
holoenzyme before DNA addition. Whereas in the cell, RNAPσA holoenzyme could be bound to DNA prior to Fdx binding.
This limitation may bias the in vitro assay toward identifying
the factors that affect Fdx binding to free RbpA-RNAP-σA

holoenzyme complex. In particular, our in vivo results support
an association between effects on RPo stability and Fdx
sensitivity. Our work indicates that RPo stability is a newly
characterized way that RbpA contributes to Fdx activity.
During transcription initiation, RPo stabilization involves
closing of the RNAP clamp module around downstream
nucleic acid as the transcription bubble is formed (38).
Structural studies indicate that Fdx inhibits transcription
initiation by trapping the mycobacterial transcription initiation
complex in an open-clamp conformation (11). In addition, Fdx
is predicted to be unable to bind the closed-clamp conformation (11). Therefore, mycobacterial transcription factors
such as RbpA and CarD that favor RPo formation (7, 8, 10)
may impact Fdx sensitivity by reducing the lifetime of openclamp RNAP complexes that Fdx can bind. Conversely, Fdx
has also been shown to decrease the afﬁnity of CarD to RNAP
in vitro (39). CarD has a lower afﬁnity to the open-clamp
RNAP complex compared to the closed-clamp RNAP complex (RPo) (7). Thus, it is possible that Fdx lowers the fraction

Table 1
Summary of the effects of RbpA and CarD mutants on ﬁdaxomicin (Fdx) sensitivity and open complex (RPo) stability, compared to WT protein

a

RbpA construct

In vitro Fdx sensitivity

In vivo Fdx sensitivity

RPo stability

RbpA72–111
RbpAR88A
RbpAR10A/E17A
CarDR25E

Decrease
No change
Decreasea
N/A

Decrease
Increase
No change
Increase

Increase
Decrease
No change
Decrease

The level of decrease in Fdx sensitivity in vitro with RbpAR10A/E17A is intermediate to that of RbpA72–111, when both are compared to RbpAWT.
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of CarD bound to RNAP-promoter complexes by reducing the
amount of RPo formed at equilibrium. This work highlights the
need to biochemically understand Fdx activity against the diversity of RNAP complexes that exist within the bacteria.
In addition to the initiation complexes formed following
RNAP-σA binding to DNA, one could envision other factors
that exist in vivo and not in vitro that could impact Fdx activity. The in vitro assays of Fdx activity also exclude RNAP
holoenzymes containing alternative σ factors and additional
RNAP interacting proteins present in the bacteria. Fdx has
been shown to be more active at inhibiting the E. coli RNAP-σs
holoenzyme compared to the E. coli RNAP-σ70 holoenzyme
(32), suggesting that the presence of alternative σ factor–
bound holoenzymes may also explain some discrepancies between our in vitro and in vivo ﬁndings. In addition to these
direct effects on RNAP, truncation of the RbpA NTT and CD
results in global dysregulation of gene expression in
M. smegmatis (5, 10), which could also affect sensitivity to Fdx.
Therefore, the effect of RbpA on Fdx activity in vivo is likely
multifactorial. As such, analysis of RbpA mutants with substitutions in conserved residues within the NTT that are
predicted to contact different domains in the RNAP-σA holoenzyme revealed diverse effects of RbpA on the Fdx sensitivity of M. smegmatis (Fig. S1). The impact of these mutants
on transcription initiation is unknown, but further investigation into this area could shed more light on how association of
RbpA on transcription initiation complexes contributes to
antibiotic susceptibility.
Collectively, our results demonstrate that the RbpA NTT
domain is a signiﬁcant contributor to the Fdx sensitivity of the
mycobacterial transcription machinery, consistent with previous studies. However, we also discover that the role for RbpA
involves more than simply providing amino acids to the Fdx
binding site. Our data support a model where multiple RbpA
domains, including the NTT, can impact Fdx sensitivity
through modulation of transcription initiation kinetics. Our
studies reveal a role for another factor that also regulates RPo
stability, CarD, in Fdx sensitivity. Fdx is currently used to treat
infections caused by C. difﬁcile, a bacterium that does not
encode an RbpA homolog but does encode CarD and other
factors that will regulate transcription by modifying RPo lifetime (1). Therefore, these studies also shed light on pathways
that can be targeted to improve Fdx activity in the clinic.

Experimental procedures
Media and bacterial strains
All M. smegmatis strains were derived from mc2155 and

grown at 37 C in LB medium supplemented with 0.5%
dextrose, 0.5% glycerol, and 0.05% Tween 80. M. smegmatis
strains expressing RbpAMtbR4A, RbpAMtbR4E, RbpAMtbL6A,
RbpAMtbR7A,
RbpAMtbR7E
RbpAMtbR10A,
RbpAMtbS15A,
E17A
R10A/E17A
R79A
RbpAMtb
and RbpAMtb
, RbpAMtb
, RbpAMt26–111
72–111
28–114
R88A
,
RbpA
,
RbpA
,
RbpA
, and
Mtb
Mtb
Msm
b
RbpAMsm72–114 were engineered using pMSG430 plasmids that
express each rbpA allele from a constitutive Pmyc1-tetO promoter and integrated into the attB site of the M. smegmatis

ΔrbpA attB::tet-rbpA strain previously described (5, 33, 34).
The primers used to make RbpA strains are in Table S1.
RbpAMtbR79A, RbpAMtbR88A, RbpAMtb26–111, and RbpAMtb72–111
have been previously described in (5). The M. smegmatis
ΔrbpA attB::tet-rbpA strains expressing RbpAMtbR4A, RbpAMtR4E
, RbpAMtbL6A, RbpAMtbR7A, RbpAMtbR7E, RbpAMtbR10A,
b
RbpAMtbS15A, RbpAMtbE17A, RbpAMtbR10A/E17A, RbpAMsm28–114,
RbpAMsm72–114, RbpAMtbR79A, and RbpAMtbR88A were named
csm455, csm461, csm456, csm457, csm458, csm451, csm462,
csm450, csm498, csm510, csm511, csm322, and csm314,
respectively.
Protein preparation for biochemical assays
Plasmids containing the M. tuberculosis H37Rv genomic
DNA encoding the different M. tuberculosis RNAP holoenzyme subunits were a gift from Jayanta Mukhopadhyay (Bose
Institute) (40). Expression and puriﬁcation were carried out in
accordance with the methods described previously (5). Recombinant M. tuberculosis RbpA proteins were puriﬁed from
E. coli as previously described using the pET-SUMO vector
(primers used to make RbpA constructs for protein puriﬁca
tion are in Table S2) (5). RbpA was stored at −80 C in
150 mM NaCl, 20 mM Tris pH 8.0, and 1 mM β-mercaptoethanol. M. tuberculosis RNAP-σA holoenzyme was stored

at −80 C in 50% glycerol, 10 mM Tris pH 7.9, 200 mM NaCl,
0.1 mM EDTA, 1 mM MgCl2, 20 μM ZnCl2, and 2 mM DTT.
Fdx zone of inhibition
M. smegmatis cultures were grown to OD600 = 0.4 to 0.8.
Based on the approximation that OD600 = 1.0 is equivalent to
5 × 108 mycobacteria, 2.5 × 108 cells were collected, resuspended in 100 μl of LB, and plated on LB agar plates. Whatman ﬁlter paper disks were applied to the plates, and 10 μl of
100 μM, 250 μM, or 500 μM Fdx (Selleck Chemicals) resuspended in DMSO or DMSO alone were added to the What
man ﬁlter paper disks. The plates were incubated at 37 C for
48 h, and the zones of inhibition were measured. The zone of
inhibition for each replicate at each drug concentration is the
average of four measurements approximately 90o apart.
3-Nucleotide in vitro transcription assay
For the Fdx studies in Figure 1, a linear 150 bp dsDNA
template containing the M. tuberculosis rrnAP3 promoter was
prepared by annealing and extending 85-mer oligonucleotide
primers (Integrated DNA Technologies) with a 20 nucleotide
overlap ranging from nucleotides 1,471,577 to 1,471,726 in the
M. tuberculosis H37Rv genome (9) and HPLC puriﬁed as
previously described (7). For the RPo stability assays in Figure 3,
a plasmid DNA template containing the M. tuberculosis
rrnAP3 promoter from the −39 to +4 positions relative to
the +1 transcription start site, ranging from nucleotides
1,471,618 to 1,471,660 in the M. tuberculosis H37Rv genome,
was used. Plasmid DNA was isolated by Midi-prep (Qiagen)
and cleaned by alcohol precipitation. For all 3-nucleotide
transcription assays, RbpA, M. tuberculosis RNAP-σA holoen
zyme, and dsDNA template were incubated at 37 C for 10 min.
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Reactions were initiated by adding 2.5 μl of a substrate mixture
containing GpU, UTP, and 32P radiolabeled UTP and incu
bating at 37 C for 10 min to allow for production of a
3-nucleotide product in 20 μl reactions that included a ﬁnal
concentration of 2 μM RbpA (saturating concentration based
on (5, 8), 100 nM M tuberculosis RNAP-σA holoenzyme, 10 nM
dsDNA template, 1 mM DTT, 0.1 mg/ml BSA (NEB), 200 μM
GpU, 20 μM UTP, 0.2 μl of 32P radiolabeled UTP, 75 mM
NaCl, 10.1 mM MgCl2, 2 μM ZnCl2, 18 mM Tris pH 8.0,
0.01 mM EDTA, 5% glycerol, and 0.1 mM β-mercaptoethanol.
Reactions were stopped with 2X formamide stop buffer (98%
[vol/vol] formamide, 5 mM EDTA and 0.05% w/v bromophenol blue). Reaction products were resolved by 22%
polyacrylamide-urea gel electrophoresis and exposure to
autoradiography ﬁlm. Products were quantiﬁed using ImageJ.
Dose–response curves were carried out the same way with the
exception that Fdx was added to RbpA and M. tuberculosis

RNAP-σA holoenzyme, incubated for 10 min at 37 C, at which
point linear dsDNA template was added and allowed to incu
bate at 37 C for 15 min before initiating the reactions with the
substrate mixture. The in vitro transcription reaction conditions are slightly different than those used in previously published work (11), including different salts in the buffers,
different type of holoenzyme preps, and a different dsDNA
template, all likely contributing to overall differences in the Fdx
IC50 values. Nonetheless, the trends between samples are
consistent between this manuscript and previously published
work, and therefore, the different reaction conditions do not
change the data interpretations or conclusions.

Data availability
All data are contained in the manuscript and the supporting
information ﬁle.
Supporting information—This
information.
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